GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » Revenue

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Revenue : $0.12 Mil (TTM As of Dec. 2020)


View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals Revenue?

Sunesis Pharmaceuticals's revenue for the three months ended in Dec. 2020 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2020 was $0.12 Mil. Sunesis Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2020 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was $0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Sunesis Pharmaceuticals Revenue Historical Data

The historical data trend for Sunesis Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Revenue Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.54 0.67 0.24 2.07 0.12

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.07 0.12 - - -

Competitive Comparison of Sunesis Pharmaceuticals's Revenue

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Revenue falls into.



Sunesis Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunesis Pharmaceuticals  (NAS:SNSS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Sunesis Pharmaceuticals Revenue Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.
Executives
Steve Carchedi director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto director 58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum director 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young director
Homer L Pearce director 84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt director, officer: See Remarks C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump director
Tina Gullotta officer: VP, Finance SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms 10 percent owner 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Headlines

From GuruFocus

Sunesis Announces Pricing of $12 Million Offering of Common Stock

By Marketwired Marketwired 07-29-2020